Pharmacoeconomics

Pharmacoeconomics is the application of economic evaluation to medicines, comparing the costs and health outcomes of drug therapies to inform decisions about their value. It provides the analytic methods - cost-effectiveness, cost-utility, cost-benefit, and cost-minimisation analysis - used to judge whether a medicine's added benefit justifies its added cost.

Definition

Pharmacoeconomics is the discipline that measures and compares the costs and consequences of pharmaceutical products and services, expressing the relationship between resources consumed and health outcomes produced to support resource-allocation decisions.

Scope

This entry covers the principal forms of pharmacoeconomic evaluation, the measurement of costs and outcomes, the incremental cost-effectiveness ratio and the quality-adjusted life-year, decision-analytic and Markov modelling, and the reporting standards that govern these studies. It is a methodological reference and does not provide clinical or prescribing guidance.

Core questions

• What are the main types of pharmacoeconomic evaluation and when is each used?
• How are costs and health outcomes measured and combined?
• What is the incremental cost-effectiveness ratio and how is it interpreted?
• How is the quality-adjusted life-year used to compare interventions?

Key concepts

• Cost-effectiveness analysis
• Cost-utility analysis
• Cost-benefit analysis
• Cost-minimisation analysis
• Incremental cost-effectiveness ratio (ICER)
• Quality-adjusted life-year (QALY)
• Willingness-to-pay threshold
• Decision-analytic and Markov modelling
• Discounting and time horizon

Mechanisms

A pharmacoeconomic evaluation pairs a measure of cost with a measure of consequence. Cost-minimisation compares costs when outcomes are equivalent; cost-effectiveness analysis relates cost to a natural outcome unit; cost-utility analysis uses the quality-adjusted life-year so that interventions across conditions can be compared; and cost-benefit analysis values outcomes in money (Drummond 2005). The central summary statistic is the incremental cost-effectiveness ratio - the difference in cost divided by the difference in effect between two options - which is compared against a willingness-to-pay threshold such as a cost-per-QALY benchmark (Neumann 2014). Decision-analytic and Markov models extrapolate costs and outcomes over time when trial data are limited, and sensitivity analysis tests how robust conclusions are to uncertainty.

Clinical relevance

Pharmacoeconomic studies inform payer and policy judgements about the value of medicines and are part of the evidence base appraised in health technology assessment. This entry describes how that evidence is generated and interpreted; it is not a basis for individual diagnostic, prescribing, or treatment decisions.

Evidence & guidelines

Methodological foundations are set out in standard texts (Drummond 2005; Gold 1996), and reporting quality is governed by the Consolidated Health Economic Evaluation Reporting Standards (CHEERS), which specify how economic evaluations should be described so that their methods and assumptions can be appraised (Husereau 2013). National HTA agencies issue reference cases that adapt these methods to their own decision contexts.

History

Cost-effectiveness analysis in health care was formalised through the 1970s and 1980s and consolidated by the 1996 report of the US Panel on Cost-Effectiveness in Health and Medicine (Gold 1996), which standardised the reference-case approach. The methods texts of Drummond and colleagues (Drummond 2005) became the field's principal reference, and reporting standards such as CHEERS (Husereau 2013) later improved the transparency and comparability of published evaluations.

Debates

What willingness-to-pay threshold should define cost-effectiveness?

Benchmarks such as the $50,000-per-QALY figure are widely cited but have weak empirical foundations, and there is ongoing debate over whether thresholds should be fixed, vary by context, or be derived from a health system's opportunity cost.

Key figures

• Michael Drummond
• Milton Weinstein
• Peter J. Neumann
• Marthe Gold

Seminal works

• drummond-2005
• gold-1996
• husereau-2013

Frequently asked questions

What is the difference between cost-effectiveness and cost-utility analysis?

Cost-effectiveness analysis measures outcomes in natural units (such as life-years gained), while cost-utility analysis uses the quality-adjusted life-year, which combines length and quality of life so that interventions across different conditions can be compared on a common scale.

What does an incremental cost-effectiveness ratio tell you?

It expresses the extra cost per extra unit of health benefit of one option compared with another, and is typically judged against a willingness-to-pay threshold to decide whether the added benefit is considered worth the added cost.